Literature DB >> 15074367

Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies.

Meral Topçu1, Hüseyin Tan, Dilek Yalnizoğlu, Alp Usubütün, Işil Saatçi, Müjgan Aynaci, Banu Anlar, Haluk Topaloğlu, Güzide Turanli, Gülşen Köse, Sabiha Aysun.   

Abstract

Neuronal ceroid lipofuscinosis (NCL) is one of the most common progressive neurodegenerative diseases seen in childhood. NCL is inherited as autosomal recessive trait, and is characterized by the accumulation of 'ceroid lipofuscin' in neuronal and extraneuronal cells. Clinical features include seizures, ataxia, myoclonus, loss of vision, and mental and motor deterioration. Although the disease is widely seen across the world, there seems to be an information gap in Asian countries. To date, no comprehensive and detailed studies on NCL have been carried out in Turkey. However, one could predict that the disease is rather frequent in Turkey due to high rates of consanguineous marriages. Thirty-six Turkish patients were evaluated in this study. Sixteen (44.5%) patients were girls, and 20 (55.5%) were boys. Parents were consanguineous in 25 families (80%). In five families (14%), the disease was seen in two sibs. The diagnosis was based on clinical evaluation, and neurophysiological, neuroradiologic, enzymatic, and histopathological studies. Electron microscopic study was the main diagnostic laboratory test. Three patients were classified as infantile NCL, 11 were late infantile NCL, 5 were juvenile type NCL and 17 patients were Turkish variant NCL. In juvenile type, major initial symptom was visual impairment, whereas in all other types seizures were predominantly the first symptom at the onset of the disease. The initial symptoms of Turkish variant NCL were similar to those of late infantile type. Similar age at clinical symptoms and the presence of visual symptoms were common features of Turkish variant and juvenile NCL. Compared to late infantile NCL, Turkish variant, showed a more severe course regarding seizures. Electroencephalogram (EEG) showed abnormal features predominantly in Turkish variant, and were remarkable for occipital spikes. In patients with Turkish variant magnetic resonance imaging of the brain showed brainstem involvement, especially pons, in all patients except one; cerebral and cerebellar atrophy were seen with a slower course compared to late infantile NCL. Clinical picture of NCL in advanced stages of the disease was similar regardless of the subtype.

Entities:  

Mesh:

Year:  2004        PMID: 15074367

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  17 in total

Review 1.  Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.

Authors:  Sara E Mole; Ruth E Williams; Hans H Goebel
Journal:  Neurogenetics       Date:  2005-09-28       Impact factor: 2.660

Review 2.  Classification and natural history of the neuronal ceroid lipofuscinoses.

Authors:  Jonathan W Mink; Erika F Augustine; Heather R Adams; Frederick J Marshall; Jennifer M Kwon
Journal:  J Child Neurol       Date:  2013-07-09       Impact factor: 1.987

3.  Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: Another genetic hit in the Mediterranean.

Authors:  Natalia Cannelli; Denise Cassandrini; Enrico Bertini; Pasquale Striano; Lucia Fusco; Roberto Gaggero; Nicola Specchio; Roberta Biancheri; Federico Vigevano; Claudio Bruno; Alessandro Simonati; Federico Zara; Filippo M Santorelli
Journal:  Neurogenetics       Date:  2006-03-29       Impact factor: 2.660

4.  Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations.

Authors:  Laura Canafoglia; Isabella Gilioli; Federica Invernizzi; Vito Sofia; Valeria Fugnanesi; Michela Morbin; Luisa Chiapparini; Tiziana Granata; Simona Binelli; Vidmer Scaioli; Barbara Garavaglia; Nardo Nardocci; Samuel F Berkovic; Silvana Franceschetti
Journal:  Neurology       Date:  2015-06-26       Impact factor: 9.910

Review 5.  Decreased T2 signal in the thalami may be a sign of lysosomal storage disease.

Authors:  Taina Autti; Raimo Joensuu; Laura Aberg
Journal:  Neuroradiology       Date:  2007-03-03       Impact factor: 2.804

6.  Expression and lysosomal targeting of CLN7, a major facilitator superfamily transporter associated with variant late-infantile neuronal ceroid lipofuscinosis.

Authors:  A Sharifi; M Kousi; C Sagné; G C Bellenchi; L Morel; M Darmon; H Hulková; R Ruivo; C Debacker; S El Mestikawy; M Elleder; A-E Lehesjoki; A Jalanko; B Gasnier; A Kyttälä
Journal:  Hum Mol Genet       Date:  2010-09-07       Impact factor: 6.150

7.  A novel mutation in the MFSD8 gene in late infantile neuronal ceroid lipofuscinosis.

Authors:  E Stogmann; S El Tawil; J Wagenstaller; A Gaber; S Edris; A Abdelhady; E Assem-Hilger; F Leutmezer; S Bonelli; C Baumgartner; F Zimprich; T M Strom; A Zimprich
Journal:  Neurogenetics       Date:  2008-10-11       Impact factor: 2.660

8.  The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter.

Authors:  Eija Siintola; Meral Topcu; Nina Aula; Hannes Lohi; Berge A Minassian; Andrew D Paterson; Xiao-Qing Liu; Callum Wilson; Ulla Lahtinen; Anna-Kaisa Anttonen; Anna-Elina Lehesjoki
Journal:  Am J Hum Genet       Date:  2007-05-14       Impact factor: 11.025

Review 9.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

10.  AAV9 Gene Therapy Increases Lifespan and Treats Pathological and Behavioral Abnormalities in a Mouse Model of CLN8-Batten Disease.

Authors:  Tyler B Johnson; Katherine A White; Jon J Brudvig; Jacob T Cain; Logan Langin; Melissa A Pratt; Clarissa D Booth; Derek J Timm; Samantha S Davis; Brandon Meyerink; Shibi Likhite; Kathrin Meyer; Jill M Weimer
Journal:  Mol Ther       Date:  2020-09-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.